Penumbra Inc (PEN) - Net Assets
Based on the latest financial reports, Penumbra Inc (PEN) has net assets worth $1.47 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.90 Billion) and total liabilities ($424.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Penumbra Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.47 Billion |
| % of Total Assets | 77.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | 49.66% |
| 10-Year Change | 435.59% |
| Growth Volatility | 17.1 |
Penumbra Inc - Net Assets Trend (2013–2025)
This chart illustrates how Penumbra Inc's net assets have evolved over time, based on quarterly financial data. See PEN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Penumbra Inc (2013–2025)
The table below shows the annual net assets of Penumbra Inc from 2013 to 2025. For live valuation and market cap data, see PEN stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.43 Billion | +24.04% |
| 2024-12-31 | $1.15 Billion | -2.38% |
| 2023-12-31 | $1.18 Billion | +18.03% |
| 2022-12-31 | $998.86 Million | +4.71% |
| 2021-12-31 | $953.93 Million | +49.57% |
| 2020-12-31 | $637.79 Million | +31.34% |
| 2019-12-31 | $485.61 Million | +14.96% |
| 2018-12-31 | $422.42 Million | +5.50% |
| 2017-12-31 | $400.41 Million | +50.22% |
| 2016-12-31 | $266.55 Million | +14.63% |
| 2015-12-31 | $232.52 Million | +1979.73% |
| 2014-12-31 | $-12.37 Million | -53.44% |
| 2013-12-31 | $-8.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Penumbra Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 25268400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $237.69 Million | 16.65% |
| Common Stock | $39.00K | 0.00% |
| Other Comprehensive Income | $4.35 Million | 0.30% |
| Other Components | $1.19 Billion | 83.04% |
| Total Equity | $1.43 Billion | 100.00% |
Penumbra Inc Competitors by Market Cap
The table below lists competitors of Penumbra Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bankinter
MC:BKT
|
$12.50 Billion |
|
CP ALL Public Company Limited
BK:CPALL
|
$12.50 Billion |
|
REA Group Ltd
AU:REA
|
$12.52 Billion |
|
TURKIYE GARANTI BANKASI AS
F:GBKB
|
$12.52 Billion |
|
Shenzhen Envicool Technology Co Ltd
SHE:002837
|
$12.44 Billion |
|
Yunnan Lincang Xinyuan Germanium Industrial Co Ltd
SHE:002428
|
$12.43 Billion |
|
SOUTH32 Ltd
AU:S32
|
$12.42 Billion |
|
United States Steel Corporation
NYSE:X
|
$12.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Penumbra Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,150,931,000 to 1,427,603,000, a change of 276,672,000 (24.0%).
- Net income of 177,687,000 contributed positively to equity growth.
- Share repurchases of 31,819,000 reduced equity.
- Other comprehensive income increased equity by 10,191,000.
- Other factors increased equity by 120,613,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $177.69 Million | +12.45% |
| Share Repurchases | $31.82 Million | -2.23% |
| Other Comprehensive Income | $10.19 Million | +0.71% |
| Other Changes | $120.61 Million | +8.45% |
| Total Change | $- | 24.04% |
Book Value vs Market Value Analysis
This analysis compares Penumbra Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.33 | $317.40 | x |
| 2014-12-31 | $-0.50 | $317.40 | x |
| 2015-12-31 | $16.35 | $317.40 | x |
| 2016-12-31 | $7.96 | $317.40 | x |
| 2017-12-31 | $11.34 | $317.40 | x |
| 2018-12-31 | $11.70 | $317.40 | x |
| 2019-12-31 | $13.40 | $317.40 | x |
| 2020-12-31 | $17.94 | $317.40 | x |
| 2021-12-31 | $25.18 | $317.40 | x |
| 2022-12-31 | $26.40 | $317.40 | x |
| 2023-12-31 | $30.06 | $317.40 | x |
| 2024-12-31 | $29.31 | $317.40 | x |
| 2025-12-31 | $36.33 | $317.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Penumbra Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.45%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.66%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.28x
- Recent ROE (12.45%) is above the historical average (2.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 4.61% | 1.25x | 0.00x | $4.91 Million |
| 2014 | 0.00% | 1.79% | 1.03x | 0.00x | $3.48 Million |
| 2015 | 1.02% | 1.27% | 0.71x | 1.13x | $-20.89 Million |
| 2016 | 5.56% | 5.63% | 0.85x | 1.16x | $-11.84 Million |
| 2017 | 1.16% | 1.40% | 0.70x | 1.19x | $-35.38 Million |
| 2018 | 1.56% | 1.48% | 0.86x | 1.22x | $-35.62 Million |
| 2019 | 9.97% | 8.85% | 0.82x | 1.37x | $-131.20K |
| 2020 | -3.00% | -3.44% | 0.68x | 1.28x | $-83.41 Million |
| 2021 | 0.27% | 0.35% | 0.60x | 1.30x | $-92.77 Million |
| 2022 | -0.20% | -0.24% | 0.62x | 1.37x | $-101.89 Million |
| 2023 | 7.71% | 8.59% | 0.68x | 1.32x | $-26.94 Million |
| 2024 | 1.22% | 1.17% | 0.78x | 1.33x | $-101.08 Million |
| 2025 | 12.45% | 12.66% | 0.77x | 1.28x | $34.93 Million |
Industry Comparison
This section compares Penumbra Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,060,892,663
- Average return on equity (ROE) among peers: -79.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Penumbra Inc (PEN) | $1.47 Billion | 0.00% | 0.29x | $12.48 Billion |
| Abbott Laboratories (ABT) | $10.66 Billion | 26.20% | 1.27x | $162.13 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-132.02 Million | 0.00% | 0.00x | $13.82 Million |
| Aethlon Medical Inc (AEMD) | $-704.50K | 0.00% | 0.00x | $1.17 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $24.31K | -2.84% | 11.78x | $1.36 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.28 Million | -44.54% | 0.25x | $6.11 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $13.77 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $1.96 Million | -680.21% | 0.05x | $4.62 Million |
| Artivion Inc (AORT) | $30.20 Million | 15.56% | 0.78x | $1.10 Billion |
| Apyx Medical Inc (APYX) | $6.39 Million | 7.83% | 0.24x | $174.61 Million |
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombecto… Read more